BAKER BROS. ADVISORS LP Q1 2025 Filing
Filed May 15, 2025
Portfolio Value
$9.0T
Holdings
89
Report Date
Q1 2025
Filing Type
13F-HR
All Holdings (89 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ONCBeiGene, Ltd. | 8,799,053 | $2.4T | 26.50% | |
| 2 | INCYIncyte Corporation | 30,739,953 | $1.9T | 20.60% | |
| 3 | ACADACADIA Pharmaceuticals Inc. | 42,877,916 | $712.2B | 7.88% | |
| 4 | MDGLMadrigal Pharmaceuticals, Inc. | 1,974,590 | $654.0B | 7.24% | |
| 5 | SMMTSummit Therapeutics Inc. | 24,424,865 | $471.2B | 5.21% | |
| 6 | IM8NInsmed Incorporated | 5,380,626 | $410.5B | 4.54% | |
| 7 | RYTMRhythm Pharmaceuticals, Inc. | 5,604,483 | $296.9B | 3.29% | |
| 8 | RVMDRevolution Medicines, Inc. | 7,936,972 | $280.7B | 3.11% | |
| 9 | KYMRKymera Therapeutics, Inc. | 5,995,929 | $164.1B | 1.82% | |
| 10 | ALKSAlkermes plc | 4,483,285 | $148.0B | 1.64% | |
| 11 | EWTXEdgewise Therapeutics, Inc. | 6,155,940 | $135.4B | 1.50% | |
| 12 | REPLReplimune Group, Inc. | 11,045,336 | $107.7B | 1.19% | |
| 13 | INSM 0.75 06/01/28Insmed Incorporated | 42,850,000 | $101.6B | 1.12% | |
| 14 | IMVTImmunovant, Inc. | 5,457,881 | $93.3B | 1.03% | |
| 15 | BCYCBicycle Therapeutics plc | 10,885,357 | $92.4B | 1.02% | |
| 16 | IMCRImmunocore Holdings plc | 2,322,656 | $68.9B | 0.76% | |
| 17 | KNSAKiniksa Pharmaceuticals International, plc | 2,818,323 | $62.6B | 0.69% | |
| 18 | ABCLAbCellera Biologics Inc. | 27,525,640 | $61.4B | 0.68% | |
| 19 | RAREUltragenyx Pharmaceutical Inc. | 1,576,114 | $57.1B | 0.63% | |
| 20 | DNLIDenali Therapeutics Inc. | 3,731,695 | $50.7B | 0.56% | |
| 21 | KODKodiak Sciences Inc. | 17,310,490 | $48.6B | 0.54% | |
| 22 | NRIXNurix Therapeutics, Inc. | 3,882,125 | $46.1B | 0.51% | |
| 23 | ARGXargenx SE | 77,760 | $46.0B | 0.51% | |
| 24 | TRDAEntrada Therapeutics, Inc. | 4,865,819 | $44.0B | 0.49% | |
| 25 | CELCCelcuity Inc. | 4,257,735 | $43.0B | 0.48% | |
| 26 | GRALGRAIL, Inc. | 1,630,125 | $41.6B | 0.46% | |
| 27 | ROIVRoivant Sciences Ltd. | 3,767,773 | $38.0B | 0.42% | |
| 28 | IMTXImmatics N.V. | 7,275,830 | $32.8B | 0.36% | |
| 29 | STOKStoke Therapeutics, Inc. | 4,633,838 | $30.8B | 0.34% | |
| 30 | CERSCerus Corporation | 19,351,087 | $26.9B | 0.30% | |
| 31 | PCVXVaxcyte, Inc. | 640,885 | $24.2B | 0.27% | |
| 32 | GLUEMonte Rosa Therapeutics, Inc. | 4,916,095 | $22.8B | 0.25% | |
| 33 | CRSPCRISPR Therapeutics AG | 654,099 | $22.3B | 0.25% | |
| 34 | AKROAkero Therapeutics, Inc. | 548,713 | $22.2B | 0.25% | |
| 35 | SERASera Prognostics, Inc. | 5,498,170 | $20.2B | 0.22% | |
| 36 | CNTACentessa Pharmaceuticals plc | 1,227,178 | $17.6B | 0.20% | |
| 37 | NGNENeurogene Inc. | 1,486,200 | $17.4B | 0.19% | |
| 38 | IDYAIDEAYA Biosciences, Inc. | 1,062,123 | $17.4B | 0.19% | |
| 39 | VRNAVerona Pharma plc | 223,843 | $14.2B | 0.16% | |
| 40 | CADLCandel Therapeutics, Inc. | 2,437,189 | $13.8B | 0.15% | |
| 41 | PRAXPraxis Precision Medicines, Inc. | 331,533 | $12.6B | 0.14% | |
| 42 | TSVT*2seventy bio, Inc. | 2,497,526 | $12.3B | 0.14% | |
| 43 | XENEXenon Pharmaceuticals Inc. | 347,408 | $11.7B | 0.13% | |
| 44 | BCAXBicara Therapeutics Inc. | 833,333 | $10.9B | 0.12% | |
| 45 | ISIIonis Pharmaceuticals, Inc. | 357,915 | $10.8B | 0.12% | |
| 46 | DBVTDBV Technologies S.A. | 1,461,425 | $10.0B | 0.11% | |
| 47 | ALMSAlumis Inc. | 1,562,500 | $9.6B | 0.11% | |
| 48 | MRUSMerus N.V. | 223,500 | $9.4B | 0.10% | |
| 49 | PRLDPrelude Therapeutics Inc. | 10,123,824 | $7.8B | 0.09% | |
| 50 | VERVVerve Therapeutics, Inc. | 1,691,530 | $7.7B | 0.09% | |
| 51 | RCKTRocket Pharmaceuticals, Inc. | 1,097,079 | $7.3B | 0.08% | |
| 52 | XNCRXencor, Inc. | 670,431 | $7.1B | 0.08% | |
| 53 | DYNDyne Therapeutics, Inc. | 672,096 | $7.0B | 0.08% | |
| 54 | KALAKALA BIO, Inc. | 1,201,894 | $6.9B | 0.08% | |
| 55 | DSGNDesign Therapeutics, Inc. | 1,743,725 | $6.7B | 0.07% | |
| 56 | GPCRStructure Therapeutics Inc. | 361,565 | $6.3B | 0.07% | |
| 57 | TSHATaysha Gene Therapies, Inc. | 4,004,756 | $5.6B | 0.06% | |
| 58 | RGLSRegulus Therapeutics Inc. | 2,694,044 | $4.7B | 0.05% | |
| 59 | 1K0IGM Biosciences, Inc. | 4,095,257 | $4.7B | 0.05% | |
| 60 | NTLAIntellia Therapeutics, Inc. | 644,116 | $4.6B | 0.05% | |
| 61 | TCE2Celldex Therapeutics, Inc. | 247,644 | $4.5B | 0.05% | |
| 62 | SIONSionna Therapeutics, Inc. | 400,000 | $4.2B | 0.05% | |
| 63 | BNTXBioNTech SE | 45,031 | $4.1B | 0.05% | |
| 64 | TCRXTScan Therapeutics, Inc. | 2,784,792 | $3.8B | 0.04% | |
| 65 | IRONDisc Medicine, Inc. | 77,050 | $3.8B | 0.04% | |
| 66 | VIRVir Biotechnology, Inc. | 542,539 | $3.5B | 0.04% | |
| 67 | SANASana Biotechnology, Inc. | 2,030,949 | $3.4B | 0.04% | |
| 68 | SGMTSagimet Biosciences Inc. | 952,996 | $3.1B | 0.03% | |
| 69 | RLAYRelay Therapeutics, Inc. | 1,160,117 | $3.0B | 0.03% | |
| 70 | WVEWave Life Sciences Ltd. | 344,063 | $2.8B | 0.03% | |
| 71 | FATEFate Therapeutics, Inc. | 3,258,402 | $2.6B | 0.03% | |
| 72 | SKYESkye Bioscience, Inc. | 1,450,638 | $2.3B | 0.03% | |
| 73 | TARAProtara Therapeutics, Inc. | 536,832 | $2.3B | 0.03% | |
| 74 | ELVNEnliven Therapeutics, Inc. | 114,833 | $2.3B | 0.03% | |
| 75 | CTNMContineum Therapeutics, Inc. | 312,500 | $2.2B | 0.02% | |
| 76 | PRMEPrime Medicine, Inc. | 1,028,466 | $2.0B | 0.02% | |
| 77 | TECXTectonic Therapeutic, Inc. | 100,000 | $1.8B | 0.02% | |
| 78 | VTVTvTv Therapeutics, Inc. | 97,314 | $1.7B | 0.02% | |
| 79 | CMPXCompass Therapeutics, Inc. | 547,498 | $1.0B | 0.01% | |
| 80 | NMRANeumora Therapeutics, Inc. | 1,034,600 | $1.0B | 0.01% | |
| 81 | HOOKHOOKIPA Pharma Inc. | 812,814 | $877.8M | 0.01% | |
| 82 | GBIOGBXGeneration Bio Co. | 1,944,945 | $787.7M | 0.01% | |
| 83 | ALGSAligos Therapeutics, Inc. | 83,055 | $685.2M | 0.01% | |
| 84 | CYPHLeap Therapeutics, Inc. | 404,744 | $123.5M | 0.00% | |
| 85 | IPSCCentury Therapeutics, Inc. | 241,684 | $115.0M | 0.00% | |
| 86 | TYRATyra Biosciences, Inc. | 10,607 | $98.6M | 0.00% | |
| 87 | ACRVAcrivon Therapeutics, Inc. | 22,809 | $46.3M | 0.00% | |
| 88 | SRZNWSurrozen, Inc. | 833,333 | $25.0M | 0.00% | |
| 89 | OPTEYOpthea Limited | 2,087,320 | $0 | 0.00% |